Global Preventive Vaccines Market (2020 to 2030) - Featuring Bio Farma, Emergent BioSolutions & GC Pharma Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Global Preventive Vaccines Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry.

Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases. According to the WHO, currently, global vaccination coverage is nearly 85%. This is believed to be responsible for preventing close to three million deaths, which would have otherwise been caused by infectious diseases, such as chickenpox, diphtheria, measles, pneumonia, tetanus, and tuberculosis. In fact, recent immunization records indicate that more than 115 million children are immunized against diphtheria, tetanus and pertussis annually.

However, vaccine development, especially against newly identified pathogens, is a challenging and time consuming process. For instance, authorities claim that although there are many initiatives investigating vaccines against the recently identified SARS-CoV-2 coronavirus strain, a viable vaccine is still a year away. Other barriers to vaccine development include lack of pathogen specific information, inadequate immunity (conferred by certain types of vaccines), existence of multiple pathogenic strains, and reversion potential (a phenomenon where a weakened pathogen intended for use as a vaccine, reverts to its infectious phenotype).

Despite the success achieved, so far, through vaccination, it is estimated that over 1.5 million children, under the age of five, die of vaccine-preventable diseases, every year. This is largely attributed to storage (loss of efficacy upon prolonged storage) and logistics-related (cold chain requirement) complexities, which impact adequate distribution and transportation of such medications to remote areas. Given the rate at which the global population is growing, the demand for vaccines is anticipated to increase significantly. In this regard, significant strides have been made in improving existing vaccine formulations, mostly focused on enhancing stability.

Recent technical advances, especially in the field of biotechnology, have heralded a new era in immunogen design for vaccine development. Moreover, many developers claim to be working on next generation preventive vaccine candidates, such as recombinant vaccines, viral vector-based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunologic memory. Further, a variety of adjuvants (substances with the innate potential to augment an immune response) have been discovered and are now available for the development of more versatile vaccine formulations. Several regional government bodies and private investors are actively financing stakeholders in this industry. Given that in the recent past there has been a marked rise in new entrants in this field, we anticipate this market to witness substantial growth in the coming years.

Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry/non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).
  • A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated, number of APIs evaluated and target patient population).
  • Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.
  • A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s), type of sponsor/collaborator, leading industry sponsors/collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
  • An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided information on investments made and recent developments in the domain.
  • An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES

7. CLINICAL TRIAL ANALYSIS

8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS

9. FUNDING AND INVESTMENT ANALYSIS

10. MARKET SIZING AND OPPORTUNITY ANALYSIS

11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

Companies Mentioned

  • 3P Biopharmaceuticals
  • Abbott Biologicals
  • AbbVie Contract Manufacturing
  • Aberdeen Proving Ground
  • ABL
  • Abu Dhabi Investment Authority
  • Abzena
  • Adimmune
  • Adjuvant Capital
  • Advagene Biopharma
  • Affinivax
  • AJ Biologics
  • AJ Vaccines
  • Ajinomoto Bio-Pharma Services
  • Alexandria Venture Investments
  • Alopexx Vaccine
  • Altimmune
  • AmbioPharm
  • AMRI
  • Anaxago
  • Angels High Tech Investments
  • Anhui Zhifei Longcom Biologic Pharmacy
  • ARCH Venture Partners
  • ArrowMark Partners
  • Astellas Pharma
  • Atlantic Methanol Production Company
  • Auro Vaccines
  • Avid Bioservices
  • AVIR Green Hills Biotechnology
  • aws Grnderfonds
  • Barr Laboratories
  • Batavia Biosciences
  • Bavarian Nordic
  • Baxter BioPharma Solutions
  • Baylor College of Medicine
  • BB Biotech
  • Beijing Center for Disease Control and Prevention
  • Beijing Institute of Biological Products
  • Beijing Minhai Biotechnology
  • Beijing Zhifei Lvzhu Biopharmaceutical
  • Bharat Biotech
  • Bharat Serums and Vaccine
  • Bill & Melinda Gates Foundation
  • Bilthoven Biologicals
  • BINEX
  • Bio Elpida
  • Bio Farma
  • BioCell
  • BioConnections
  • Any Many Many More Companies!

For more information about this report visit https://www.researchandmarkets.com/r/mndnib

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900